TA29 Leukaemia (lymphocytic) - fludarabine: review proposal - October 2013
Review of NICE Technology Appraisal Guidance No.29; Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
Proposal to move the existing guidance to the static list
The original review date for this appraisal was August 2004.
This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.
Having looked at the available evidence again, the Institute has not identified any new evidence that would lead to a change in the existing recommendations. Consequently we propose that TA29 should move to the static list of technology appraisals.
Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance. Please see appendix A for a full list of the organisations we have contacted.
This page was last updated: 21 October 2013